September 14, 2021 10:36 AM EDT
Bioregnum
R&D

#ES­MO21 is loom­ing, and we have a great group of ex­perts lined up to help make sense of the news

The one in­ter­na­tion­al sci­ence con­fer­ence I al­ways en­joyed at­tend­ing most has been ES­MO. You mix some high-oc­tane can­cer R&D news with one of the best …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times